NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00770081
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
🇺🇸Renal Endocrine Associates, P. C., Pittsburgh, Pennsylvania, United States
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 349
- Registration Number
- NCT00765830
- Locations
- 🇪🇸
Hospital de la Ribera, Alzira, Spain
🇪🇸Hospital San Pedro de Alcantara, Caceres, Spain
🇪🇸Clinica Mediterranea de Neurociencias, Alicante, Spain
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 525
- Registration Number
- NCT00759200
- Locations
- 🇹🇭
Novartis Investigative site, Chaingmai, Thailand
🇬🇧Novartis Investigative Site, Glasgow, United Kingdom
Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00746330
- Locations
- 🇵🇪
Novartis Investigative Site, Lima, Peru
Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00736047
- Locations
- 🇩🇪
Novartis Investigator Site, Neuss, Germany
🇩🇪Novartis Investigative Site, Mainz, Germany
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00733863
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
🇸🇪Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
🇬🇧Moorgreen Hospital, Southampton, United Kingdom
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00732771
- Locations
- 🇫🇷
Novartis Investigator Site, France, France